Sugi Predict

Sugi Predict / Compounds / SCHEMBL2333358

SCHEMBL2333358

SCHEMBL2333358

CC(C)(C)OC(=O)NC(Cc1cccc(Br)c1)C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 7/20 0.74
▸ CTSK P43235 6/20 0.74
▸ CTSB P07858 4/20 0.74
▸ ACE P12821 2/20 0.64
▸ CTSL P07711 2/20 0.55
▸ PPARA Q07869 2/20 0.53
▸ PPARG P37231 1/20 0.53
▸ PTPN1 P18031 2/20 0.53
▸ ITGB3 P05106 2/20 0.52
▸ ITGA2B P08514 2/20 0.52
▸ ITGB1 P05556 1/20 0.51
▸ ITGAV P06756 1/20 0.51
▸ ITGB5 P18084 1/20 0.51
▸ APP P05067 1/20 0.49
▸ MAPK1 P28482 1/20 0.48
▸ KLK5 Q9Y337 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758057 1.00 CTSS (0.74) CTSSCTSKCTSBACECTSL
SCHEMBL3553426 1.00 CTSS (0.74) CTSSCTSKCTSBACECTSL
SCHEMBL30655726 1.00 CTSS (0.74) CTSSCTSKCTSBACECTSL
SCHEMBL1073538 1.00 CTSS (0.74) CTSSCTSKCTSBACECTSL
SCHEMBL30829402 1.00 CTSS (0.74) CTSSCTSKCTSBACECTSL
SCHEMBL20905314 0.90 CTSS (0.71) CTSSCTSKCTSBACECTSL
SCHEMBL27350854 0.90 CTSS (0.71) CTSSCTSKCTSBACECTSL
SCHEMBL30578593 0.89 CTSS (0.69) CTSSCTSKCTSBACECTSL
SCHEMBL29657242 0.89 CTSS (0.69) CTSSCTSKCTSBACECTSL
SCHEMBL2346583 0.89 CTSS (0.69) CTSSCTSKCTSBACECTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034111-A1 NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS CAYMAN CHEMICAL COMPANY INCORPORATED (US) 2026-02-05 — — US disclosed
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2025-11-18 — — US disclosed
US-20250066386-A1 INHIBITORS OF KRAS BIOMEA FUSION, INC. 2025-02-27 — — US disclosed
CN-117480164-B Factor XIa inhibitor and preparation method and application thereof 上海领泰生物医药科技有限公司 2024-07-05 — — CN disclosed
CN-118234731-A RAS inhibitors 锐新医药公司 2024-06-21 — — CN disclosed
CN-114656379-B Synthesis method of ritalst intermediate 成都道合尔医药技术有限公司 2024-06-04 — — CN disclosed
CN-114656379-B Synthesis method of ritalst intermediate 成都道合尔医药技术有限公司 2024-06-04 — — CN disclosed
EP-3914256-B1 GPR35 MODULATORS PROMETHEUS BIOSCIENCES INC (US) 2024-05-29 — — EP disclosed
US-11952352-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2024-04-09 — — US disclosed
CN-117715658-A Method for inhibiting RAS 锐新医药公司 2024-03-15 — — CN disclosed
US-7297816-B2 Sulfonamide compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-20 — — US disclosed
EP-1490371-B1 THIOPHENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL MYERS SQUIBB CO (US) 2007-08-15 — — EP disclosed
EP-1797083-A1 SULFONAMIDE COMPOUNDS Janssen Pharmaceutica, N.V. (BE) 2007-06-20 — — EP disclosed
WO-2006036670-A1 SULFONAMIDE COMPOUNDS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-06 — — WO disclosed
US-20060069286-A1 Sulfonamide compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2006-03-30 — — US disclosed
EP-1490371-A4 THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL MYERS SQUIBB CO (US) 2006-03-22 — — EP disclosed
US-6933294-B2 Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2005-08-23 — — US disclosed
EP-1490371-A1 THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME Bristol-Myers Squibb Company (US) 2004-12-29 — — EP disclosed
US-20040058930-A1 Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY 2004-03-25 — — US disclosed
WO-2003084959-A1 THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2003-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066386-A1 INHIBITORS OF KRAS KRAS, NRAS, HRAS CTSS 2174/4885CTSK 2256/4885CTSB 2032/4885
US-20040058930-A1 Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same ABCG2, PFAS, CYP2F1 CTSS 461/4885CTSK 535/4885CTSB 890/4885
US-20260034111-A1 NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS PLA2G2F, PLA2R1, PLA2G12A CTSS 485/4885CTSK 594/4885CTSB 420/4885
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors PSMB5, PSMB1, PSMB3 CTSS 640/4885CTSK 1101/4885CTSB 466/4885
US-20060069286-A1 Sulfonamide compounds CCKAR, CCKBR, TAS1R2 CTSS 1297/4885CTSK 2606/4885CTSB 1992/4885
US-11952352-B2 Ras inhibitors KRAS, NRAS, HRAS CTSS 1023/4885CTSK 1458/4885CTSB 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.